Article

Successful Treatment of an Adult Diffuse Midline Glioma With Olaparib Combined With Bevacizumab

2021-03-02

Abstract excerpt

Diffuse midline gliomas (DMGs), characterized by malignant, fast growing and carrying a poor prognosis, are a rare subtype of glial tumor. Majority of DMGs harboring H3 K27-mutation are a novel entity with a worse prognosis and are categorized as a grade IV glioma. Histone-mutated DMGs characterized by a midline location occur more commonly in children and less frequently in adults. Considering the treatment is li...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c097ca6c-178e-5d33-a6f9-5f24e3107989
DOI: 10.21203/rs.3.rs-260981/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Successful Treatment of an Adult Diffuse Midline Glioma With Olaparib Combined With BevacizumabDOI 10.21203/rs.3.rs-260981/v1Read

[Diffuse midline glioma].Semantic proximity Read

How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.Semantic proximity Read

Diffuse midline glioma treated with epigenetic agent-based immunotherapySemantic proximity Read

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read

H3K27M mutant diffuse midline glioma: a case report.Semantic proximity Read

A Clinicopathological Analysis on Diffuse Midline Glioma in AdultsSemantic proximity Read

Clinical practice guidelines for the management of adult diffuse gliomas.Semantic proximity Read

H3K27M-mutant Diffuse Midline Gliomas should be Further Molecularly Stratified: An Integrated Analysis of 669 PatientsSemantic proximity Read

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionSemantic proximity Read

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read